메뉴 건너뛰기




Volumn 16, Issue 1, 2016, Pages 67-78

Evolocumab: A Review in Hyperlipidemia

Author keywords

[No Author keywords available]

Indexed keywords

EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ANTILIPEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE;

EID: 84956616206     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-015-0153-0     Document Type: Article
Times cited : (11)

References (59)
  • 1
    • 79960205374 scopus 로고    scopus 로고
    • ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
    • PID: 21882396, COI: 1:CAS:528:DC%2BC3MXptVyrtbo%3D
    • Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3–46.
    • (2011) Atherosclerosis. , vol.217 , Issue.1 , pp. 3-46
    • Catapano, A.L.1    Reiner, Z.2    De Backer, G.3
  • 2
    • 84897970506 scopus 로고    scopus 로고
    • 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • PID: 24222016
    • Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.
    • (2014) Circulation. , vol.129 , pp. S1-S45
    • Stone, N.J.1    Robinson, J.G.2    Lichtenstein, A.H.3
  • 3
    • 84896369977 scopus 로고    scopus 로고
    • Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation
    • PID: 24636175
    • Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014;8(2):148–72.
    • (2014) J Clin Lipidol. , vol.8 , Issue.2 , pp. 148-172
    • Watts, G.F.1    Gidding, S.2    Wierzbicki, A.S.3
  • 4
    • 84900832381 scopus 로고    scopus 로고
    • The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies
    • PID: 24632267, COI: 1:CAS:528:DC%2BC2cXmtFWjtLg%3D
    • Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63(19):1935–47.
    • (2014) J Am Coll Cardiol. , vol.63 , Issue.19 , pp. 1935-1947
    • Sniderman, A.D.1    Tsimikas, S.2    Fazio, S.3
  • 5
    • 84897889156 scopus 로고    scopus 로고
    • PCSK9: a key modulator of cardiovascular health
    • PID: 24625727, COI: 1:CAS:528:DC%2BC2cXktF2lurc%3D
    • Seidah NG, Awan Z, Chretien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114(6):1022–36.
    • (2014) Circ Res. , vol.114 , Issue.6 , pp. 1022-1036
    • Seidah, N.G.1    Awan, Z.2    Chretien, M.3
  • 6
    • 84956626117 scopus 로고    scopus 로고
    • European Medicines Agency. Repatha (evolocumab): EU summary of product characteristics. 2015. Accessed 9 Nov 2015
    • European Medicines Agency. Repatha (evolocumab): EU summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 9 Nov 2015.
  • 7
    • 85018198287 scopus 로고    scopus 로고
    • ® (evolocumab) injection
    • ® (evolocumab) injection, for subcutaneous use: US prescribing information. 2015. http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf. Accessed 9 Nov 2015.
    • (2015) for subcutaneous use: US prescribing information
  • 8
    • 84956641309 scopus 로고    scopus 로고
    • Health Canada. Repatha (evolocumab) solution for subcutaneous injection: Canadian product monograph. 2015. Accessed 9 Nov 2015
    • Health Canada. Repatha (evolocumab) solution for subcutaneous injection: Canadian product monograph. 2015. http://www.hc-sc.gc.ca/. Accessed 9 Nov 2015.
  • 10
    • 84868206496 scopus 로고    scopus 로고
    • Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins
    • PID: 23083772, COI: 1:CAS:528:DC%2BC38Xhs1WqtbjF
    • Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60(19):1888–98.
    • (2012) J Am Coll Cardiol. , vol.60 , Issue.19 , pp. 1888-1898
    • Dias, C.S.1    Shaywitz, A.J.2    Wasserman, S.M.3
  • 11
    • 85047289582 scopus 로고    scopus 로고
    • Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study
    • PID: 26228031, COI: 1:CAS:528:DC%2BC2MXhsFCrtbrF
    • Blom DJ, Djedjos CS, Monsalvo ML, et al. Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ Res. 2015;117(8):731–41.
    • (2015) Circ Res. , vol.117 , Issue.8 , pp. 731-741
    • Blom, D.J.1    Djedjos, C.S.2    Monsalvo, M.L.3
  • 12
    • 84899846576 scopus 로고    scopus 로고
    • A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
    • PID: 24678979, COI: 1:CAS:528:DC%2BC2cXot12jtbw%3D
    • Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–19.
    • (2014) N Engl J Med. , vol.370 , Issue.19 , pp. 1809-1819
    • Blom, D.J.1    Hala, T.2    Bolognese, M.3
  • 13
    • 84956695924 scopus 로고    scopus 로고
    • European Medicines Agency. Repatha (evolocumab): EU assessment report. 2015. Accessed 9 Nov 2015
    • European Medicines Agency. Repatha (evolocumab): EU assessment report. 2015. http://www.ema.europa.eu/. Accessed 9 Nov 2015.
  • 14
    • 84939811997 scopus 로고    scopus 로고
    • Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology
    • PID: 26293511, COI: 1:CAS:528:DC%2BC2MXhsl2ntLvF
    • Page MM, Watts GF. Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Expert Opin Drug Metab Toxicol. 2015;11(9):1505–15.
    • (2015) Expert Opin Drug Metab Toxicol. , vol.11 , Issue.9 , pp. 1505-1515
    • Page, M.M.1    Watts, G.F.2
  • 15
    • 84973873136 scopus 로고    scopus 로고
    • Evolocumab pharmacokinetics and its effects on LDL-C and PCSK9 lowering in subjects with mild or moderate hepatic impairment [abstract no. PII-034]
    • Emery MG, Gibbs JP, Slatter JG, et al. Evolocumab pharmacokinetics and its effects on LDL-C and PCSK9 lowering in subjects with mild or moderate hepatic impairment [abstract no. PII-034]. Clin Pharmacol Ther. 2015;97(Suppl 1):S69.
    • (2015) Clin Pharmacol Ther. , vol.97 , pp. S69
    • Emery, M.G.1    Gibbs, J.P.2    Slatter, J.G.3
  • 16
    • 84994302259 scopus 로고    scopus 로고
    • Relationship of body weight and dosing of evolocumab (EVO) for the treatment of hypercholesterolemia [abstract no. P5984]
    • Mahlof E, Koren M, Emery M, et al. Relationship of body weight and dosing of evolocumab (EVO) for the treatment of hypercholesterolemia [abstract no. P5984]. Eur Heart J. 2015;36(Suppl):1048.
    • (2015) Eur Heart J. , vol.36 , pp. 1048
    • Mahlof, E.1    Koren, M.2    Emery, M.3
  • 17
    • 84869220345 scopus 로고    scopus 로고
    • Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial
    • PID: 23129602, COI: 1:CAS:528:DC%2BC38Xhs1Oltb7P
    • Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408–17.
    • (2012) Circulation. , vol.126 , Issue.20 , pp. 2408-2417
    • Raal, F.1    Scott, R.2    Somaratne, R.3
  • 18
    • 84870478439 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
    • PID: 23141813, COI: 1:CAS:528:DC%2BC38Xhs1Cjs73O
    • Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007–17.
    • (2012) Lancet. , vol.380 , Issue.9858 , pp. 2007-2017
    • Giugliano, R.P.1    Desai, N.R.2    Kohli, P.3
  • 19
    • 84899633509 scopus 로고    scopus 로고
    • Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk: primary results from the phase 2 YUKAWA study
    • PID: 24662398, COI: 1:CAS:528:DC%2BC2cXhtVagsrnP
    • Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk: primary results from the phase 2 YUKAWA study. Circ J. 2014;78(5):1073–82.
    • (2014) Circ J. , vol.78 , Issue.5 , pp. 1073-1082
    • Hirayama, A.1    Honarpour, N.2    Yoshida, M.3
  • 20
    • 84871326497 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial
    • PID: 23128163, COI: 1:CAS:528:DC%2BC3sXkt1ChtQ%3D%3D
    • Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497–506.
    • (2012) JAMA. , vol.308 , Issue.23 , pp. 2497-2506
    • Sullivan, D.1    Olsson, A.G.2    Scott, R.3
  • 21
    • 84870494510 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
    • PID: 23141812, COI: 1:CAS:528:DC%2BC38Xhs1CjsLzM
    • Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995–2006.
    • (2012) Lancet. , vol.380 , Issue.9858 , pp. 1995-2006
    • Koren, M.J.1    Scott, R.2    Kim, J.B.3
  • 22
    • 84921483643 scopus 로고    scopus 로고
    • PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
    • PID: 25282519, COI: 1:CAS:528:DC%2BC2cXhs1Ortr3I
    • Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–40.
    • (2015) Lancet. , vol.385 , Issue.9965 , pp. 331-340
    • Raal, F.J.1    Stein, E.A.2    Dufour, R.3
  • 23
    • 84900303213 scopus 로고    scopus 로고
    • Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
    • PID: 24825642
    • Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–82.
    • (2014) JAMA. , vol.311 , Issue.18 , pp. 1870-1882
    • Robinson, J.G.1    Nedergaard, B.S.2    Rogers, W.J.3
  • 24
    • 84931091722 scopus 로고    scopus 로고
    • Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: results from the phase III YUKAWA 2 study [abstract no. 1107-104 plus poster]
    • Kiyosue A, Honarpour N, Xue A, et al. Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: results from the phase III YUKAWA 2 study [abstract no. 1107-104 plus poster]. J Am Coll Cardiol. 2015;65(10 Suppl):A1369.
    • (2015) J Am Coll Cardiol. , vol.65 , pp. A1369
    • Kiyosue, A.1    Honarpour, N.2    Xue, A.3
  • 25
    • 84902157271 scopus 로고    scopus 로고
    • Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
    • PID: 24694531, COI: 1:CAS:528:DC%2BC2cXpslCrtbY%3D
    • Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–8.
    • (2014) J Am Coll Cardiol. , vol.63 , Issue.23 , pp. 2541-2548
    • Stroes, E.1    Colquhoun, D.2    Sullivan, D.3
  • 26
    • 84902142901 scopus 로고    scopus 로고
    • Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
    • PID: 24691094, COI: 1:CAS:528:DC%2BC2cXpslCrtbc%3D
    • Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531–40.
    • (2014) J Am Coll Cardiol. , vol.63 , Issue.23 , pp. 2531-2540
    • Koren, M.J.1    Lundqvist, P.2    Bolognese, M.3
  • 28
    • 84941175248 scopus 로고    scopus 로고
    • Evaluation of the relationship between evolocumab 140 mg every two weeks and 420 mg monthly dosing regimens
    • Wasserman SM, Koren MJ, Giugliano RP, et al. Evaluation of the relationship between evolocumab 140 mg every two weeks and 420 mg monthly dosing regimens. Circulation. 2014;130:A16270.
    • (2014) Circulation. , vol.130 , pp. A16270
    • Wasserman, S.M.1    Koren, M.J.2    Giugliano, R.P.3
  • 29
    • 84941176973 scopus 로고    scopus 로고
    • Clinical equivalence of evolocumab 140 mg every two weeks and 420 mg monthly dosing regimens: a pooled analysis of 3146 patients in phase 3 studies [abstract no. 1107-103]
    • Stein EA, Koren M, Honarpour N, et al. Clinical equivalence of evolocumab 140 mg every two weeks and 420 mg monthly dosing regimens: a pooled analysis of 3146 patients in phase 3 studies [abstract no. 1107-103]. J Am Coll Cardiol. 2015;65(10 Suppl 1):A1368.
    • (2015) J Am Coll Cardiol , vol.65 , pp. A1368
    • Stein, E.A.1    Koren, M.2    Honarpour, N.3
  • 30
    • 84994230637 scopus 로고    scopus 로고
    • Clinical equivalence of evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies [abstract no. P1756 plus poster]
    • Stroes E, Robinson J, Raal F, et al. Clinical equivalence of evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies [abstract no. P1756 plus poster]. Eur Heart J. 2015;36(Suppl):307–8.
    • (2015) Eur Heart J. , vol.36 , pp. 307-308
    • Stroes, E.1    Robinson, J.2    Raal, F.3
  • 31
    • 85018196312 scopus 로고    scopus 로고
    • A multi-center, randomized study in subjects with primary hypercholesterolemia or mixed dyslipidemia [ClinicalTrials.gov identifier NCT01849497] US National Institutes of Health
    • Amgen. A multi-center, randomized study in subjects with primary hypercholesterolemia or mixed dyslipidemia [ClinicalTrials.gov identifier NCT01849497] US National Institutes of Health, ClinicalTrials.gov. 2015. http://www.clinicaltrials.gov. Accessed 9 Nov 2015.
    • (2015) ClinicalTrials.gov
  • 32
    • 85018196943 scopus 로고    scopus 로고
    • A randomized, multi-center study in subjects with hypercholesterolemia or mixed dyslipidemia [ClinicalTrials.gov identifier NCT01879319] US National Institutes of Health
    • Amgen. A randomized, multi-center study in subjects with hypercholesterolemia or mixed dyslipidemia [ClinicalTrials.gov identifier NCT01879319] US National Institutes of Health, ClinicalTrials.gov. 2015. http://www.clinicaltrials.gov. Accessed 9 Nov 2015.
    • (2015) ClinicalTrials.gov
  • 33
    • 84926206074 scopus 로고    scopus 로고
    • Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
    • PID: 25773607, COI: 1:CAS:528:DC%2BC2MXotFGlsL8%3D
    • Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9.
    • (2015) N Engl J Med. , vol.372 , Issue.16 , pp. 1500-1509
    • Sabatine, M.S.1    Giugliano, R.P.2    Wiviott, S.D.3
  • 34
    • 85018199682 scopus 로고    scopus 로고
    • Two year analysis of the safety and tolerability of evolocumab: the OSLER-1 study [abstract no. 914-10]
    • Koren MJ, Giugliano R, Raal F, et al. Two year analysis of the safety and tolerability of evolocumab: the OSLER-1 study [abstract no. 914-10]. J Am Coll Cardiol. 2015;65(10 Suppl 1):A1364.
    • (2015) J Am Coll Cardiol , vol.65 , pp. A1364
    • Koren, M.J.1    Giugliano, R.2    Raal, F.3
  • 35
    • 84887164358 scopus 로고    scopus 로고
    • Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia
    • PID: 24014831, COI: 1:CAS:528:DC%2BC3sXhslaqu7fI
    • Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113–20.
    • (2013) Circulation. , vol.128 , Issue.19 , pp. 2113-2120
    • Stein, E.A.1    Honarpour, N.2    Wasserman, S.M.3
  • 36
    • 84921459685 scopus 로고    scopus 로고
    • Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
    • PID: 25282520, COI: 1:CAS:528:DC%2BC2cXhs1OrtrvN
    • Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341–50.
    • (2015) Lancet. , vol.385 , Issue.9965 , pp. 341-350
    • Raal, F.J.1    Honarpour, N.2    Blom, D.J.3
  • 38
    • 84941173326 scopus 로고    scopus 로고
    • Long-term treatment with evolocumab in patients with homozygous familial hypercholesterolaemia (HoFH): interim results from the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders (TAUSSIG) study [abstract]
    • Raal F, Hovingh K, Blom D, et al. Long-term treatment with evolocumab in patients with homozygous familial hypercholesterolaemia (HoFH): interim results from the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders (TAUSSIG) study [abstract]. In: 17th International Symposium on Atherosclerosis. 2015.
    • (2015) 17th International Symposium on Atherosclerosis
    • Raal, F.1    Hovingh, K.2    Blom, D.3
  • 39
    • 84979853339 scopus 로고    scopus 로고
    • LDL cholesterol reduction in elderly patients with the PCSK 9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of 1779 patients in phase 2, 3 and open label extension studies [abstract no. 1107-101]
    • Koren M, Rosenson R, Khan B, et al. LDL cholesterol reduction in elderly patients with the PCSK 9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of 1779 patients in phase 2, 3 and open label extension studies [abstract no. 1107-101]. J Am Coll Cardiol. 2015;65(10 Suppl 1):A1366.
    • (2015) J Am Coll Cardiol , vol.65 , pp. A1366
    • Koren, M.1    Rosenson, R.2    Khan, B.3
  • 40
    • 84938427621 scopus 로고    scopus 로고
    • A comprehensive safety analysis of 6026 patients from phase 2 and 3 short and long term clinical trials with evolocumab (AMG 145) [abstract no. 1164 M-07 plus poster]
    • Toth PP, Sattar N, Genest J, et al. A comprehensive safety analysis of 6026 patients from phase 2 and 3 short and long term clinical trials with evolocumab (AMG 145) [abstract no. 1164 M-07 plus poster]. J Am Coll Cardiol. 2015;65(10 Suppl):A1351.
    • (2015) J Am Coll Cardiol. , vol.65 , pp. A1351
    • Toth, P.P.1    Sattar, N.2    Genest, J.3
  • 41
    • 84994324789 scopus 로고    scopus 로고
    • Long-term safety and efficacy of evolocumab in patients with statin intolerance [abstract no. P5968]
    • Cho L, Dent R, Stroes E, et al. Long-term safety and efficacy of evolocumab in patients with statin intolerance [abstract no. P5968]. Eur Heart J. 2015;36(Suppl):1043.
    • (2015) Eur Heart J. , vol.36 , pp. 1043
    • Cho, L.1    Dent, R.2    Stroes, E.3
  • 42
    • 78649888517 scopus 로고    scopus 로고
    • Lipoprotein(a) as a cardiovascular risk factor: current status
    • PID: 20965889, COI: 1:CAS:528:DC%2BC3cXhsFantLvJ
    • Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53.
    • (2010) Eur Heart J. , vol.31 , Issue.23 , pp. 2844-2853
    • Nordestgaard, B.G.1    Chapman, M.J.2    Ray, K.3
  • 43
    • 84897471477 scopus 로고    scopus 로고
    • Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials
    • PID: 24509273, COI: 1:CAS:528:DC%2BC2cXltl2msbo%3D
    • Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63(13):1278–88.
    • (2014) J Am Coll Cardiol. , vol.63 , Issue.13 , pp. 1278-1288
    • Raal, F.J.1    Giugliano, R.P.2    Sabatine, M.S.3
  • 44
    • 84929493809 scopus 로고    scopus 로고
    • Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor
    • PID: 25778403, COI: 1:CAS:528:DC%2BC2MXnsFCrsLw%3D
    • Romagnuolo R, Scipione CA, Boffa MB, et al. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015;290(18):11649–62.
    • (2015) J Biol Chem. , vol.290 , Issue.18 , pp. 11649-11662
    • Romagnuolo, R.1    Scipione, C.A.2    Boffa, M.B.3
  • 45
    • 85018194575 scopus 로고    scopus 로고
    • Praluent™ (alirocumab) injection
    • Sanofi. Praluent™ (alirocumab) injection, for subcutaneous use: US prescribing information. 2015. http://products.sanofi.us/praluent/praluent.pdf. Accessed 9 Nov 2015.
    • (2015) for subcutaneous use: US prescribing information
  • 46
    • 84956701773 scopus 로고    scopus 로고
    • European Medicines Agency. Praluent (alirocumab): EU summary of product characteristics. 2015. Accessed 9 Nov 2015
    • European Medicines Agency. Praluent (alirocumab): EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 9 Nov 2015.
  • 47
    • 84942500745 scopus 로고    scopus 로고
    • Alirocumab: first global approval
    • PID: 26370210, COI: 1:CAS:528:DC%2BC2MXhsFCju73O
    • Markham A. Alirocumab: first global approval. Drugs. 2015;75(14):1699–705.
    • (2015) Drugs. , vol.75 , Issue.14 , pp. 1699-1705
    • Markham, A.1
  • 48
    • 84931849550 scopus 로고    scopus 로고
    • Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis
    • PID: 25915661
    • Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):40–51.
    • (2015) Ann Intern Med. , vol.163 , Issue.1 , pp. 40-51
    • Navarese, E.P.1    Kolodziejczak, M.2    Schulze, V.3
  • 49
    • 84935001755 scopus 로고    scopus 로고
    • Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
    • PID: 26099511
    • Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.
    • (2015) BMC Med. , vol.13 , pp. 123
    • Zhang, X.L.1    Zhu, Q.Q.2    Zhu, L.3
  • 50
    • 84956618612 scopus 로고    scopus 로고
    • Pfizer Inc. Pfizer launches first annual PCSK9 competitive grants program to advance cardiovascular disease research. 2015. Accessed 9 Nov 2015
    • Pfizer Inc. Pfizer launches first annual PCSK9 competitive grants program to advance cardiovascular disease research. 2015. http://press.pfizer.com/press-release/pfizer-launches-first-annual-pcsk9-competitive-grants-program-advance-cardiovascular-d. Accessed 9 Nov 2015.
  • 51
    • 84921528143 scopus 로고    scopus 로고
    • Familial hypercholesterolaemia: PCSK9 inhibitors are coming
    • PID: 25282517
    • Santos RD, Watts GF. Familial hypercholesterolaemia: PCSK9 inhibitors are coming. Lancet. 2015;385(9965):307–10.
    • (2015) Lancet. , vol.385 , Issue.9965 , pp. 307-310
    • Santos, R.D.1    Watts, G.F.2
  • 52
    • 84956706247 scopus 로고    scopus 로고
    • European Medicines Agency. Lojuxta (lomitapide): EU summary of product characteristics. 2015. Accessed 9 Nov 2015
    • European Medicines Agency. Lojuxta (lomitapide): EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 9 Nov 2015.
  • 53
    • 84956640116 scopus 로고    scopus 로고
    • European Medicines Agency. Kynamro (mipomersen): scientific conclusions and grounds for refusal presented by the European Medicines Agency. 2013. Accessed 9 Nov 2015
    • European Medicines Agency. Kynamro (mipomersen): scientific conclusions and grounds for refusal presented by the European Medicines Agency. 2013. http://www.ema.europa.eu. Accessed 9 Nov 2015.
  • 54
    • 0024519925 scopus 로고
    • Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
    • PID: 2619783, COI: 1:STN:280:DyaL1M7otFymsA%3D%3D
    • Iso H, Jacobs DR, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320(14):904–10.
    • (1989) N Engl J Med. , vol.320 , Issue.14 , pp. 904-910
    • Iso, H.1    Jacobs, D.R.2    Wentworth, D.3
  • 55
    • 33746895436 scopus 로고    scopus 로고
    • High-dose atorvastatin after stroke or transient ischemic attack
    • PID: 16899775, COI: 1:CAS:528:DC%2BD28XotVKgtb8%3D
    • Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59.
    • (2006) N Engl J Med. , vol.355 , Issue.6 , pp. 549-559
    • Amarenco, P.1    Bogousslavsky, J.2    Callahan, A.3
  • 56
    • 84892679366 scopus 로고    scopus 로고
    • Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial
    • PID: 24255061, COI: 1:CAS:528:DC%2BC2cXpsl2gug%3D%3D
    • Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014;129(2):234–43.
    • (2014) Circulation. , vol.129 , Issue.2 , pp. 234-243
    • Koren, M.J.1    Giugliano, R.P.2    Raal, F.J.3
  • 57
    • 84956613976 scopus 로고    scopus 로고
    • Safety and tolerability of very low LDL-C levels in patients treated with 52 weeks of evolocumab (AMG 145)
    • Koren MJ, Blom D, Giugliano RP, et al. Safety and tolerability of very low LDL-C levels in patients treated with 52 weeks of evolocumab (AMG 145). Circulation. 2014;130:A16865.
    • (2014) Circulation. , vol.130 , pp. A16865
    • Koren, M.J.1    Blom, D.2    Giugliano, R.P.3
  • 58
    • 85018197679 scopus 로고    scopus 로고
    • LDL-C lowering efficacy of evolocumab (AMG 145) could reduce apheresis in patients at high risk for cardiovascular events in Germany [abstract no. PCV183]
    • Villa G, Schmid T, Lothgren M, et al. LDL-C lowering efficacy of evolocumab (AMG 145) could reduce apheresis in patients at high risk for cardiovascular events in Germany [abstract no. PCV183]. Value Health. 2014;17(7):A504–5.
    • (2014) Value Health. , vol.17 , Issue.7 , pp. A504-A505
    • Villa, G.1    Schmid, T.2    Lothgren, M.3
  • 59
    • 85018194177 scopus 로고    scopus 로고
    • PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value
    • Comparative Effectiveness Public Advisory Council. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks draft report. 2015. http://cepac.icer-review.org/wp-content/uploads/2015/04/PCSK9_Draft_Report_0908151.pdf. Accessed 9 Nov 2015.
    • (2015) and value-based price benchmarks draft report


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.